COVID-19

FinnGen is one of the first data contributors to the global COVID-19 host genetics initiative.

The COVID-19 pandemic is a global crisis creating severe disruptions across the economy and health system. Insights into how to better understand and treat COVID-19 are desperately needed. Given the importance and urgency in obtaining these insights, it is critical for the scientific community to come together around this shared purpose.

The COVID-19 host genetics initiative brings together the human genetics community to generate, share, and analyze data to learn the genetic determinants of COVID-19 susceptibility, severity, and outcomes. FinnGen is one of the data contributors to this important initiative. COVID-19 status of FinnGen participants is based on the Finnish National Infectious Diseases Register and regularly updated.

See the initiative's meta-analysis page for up-to-date results.

The current FinnGen COVID-19 susceptibility GWAS release (Mar 9):

2,316 cases tested positive for COVID-19
278,572 population controls

Summary statistics data can be directly downloaded:

The current FinnGen COVID-19 severity GWAS release (Mar 9):

255 cases tested positive for COVID-19 and hospitalized
278,572 population controls

Summary statistics data can be directly downloaded:

FinnGen in brief

FinnGen is a large public-private partnership aiming to collect and analyse genome and health data from 500,000 Finnish biobank participants. FinnGen aims on one hand to provide novel medically and therapeutically relevant insights but also construct a world-class resource that can be applied for future studies.

FinnGen is one of the very first personalized medicine projects at this scale and the public-private collaborative nature of the project is exceptional compared to many ongoing studies. FinnGen brings together Finnish universities, hospitals and hospital districts, THL, Blood Service, biobanks, FINBB and international pharmaceutical companies and hundreds of thousands of Finns. Because collaboration is the key to achieving breakthroughs in disease prevention, diagnosis, and treatment, we welcome everyone on this journey into our shared heritage.